Citation: | XIAN Zhiran, SUN Chunmeng, LUO Xuefang, ZHONG Wenying. Profiling of genotoxic impurities in a lidocaine hydrochloride injection[J]. Journal of China Pharmaceutical University, 2020, 51(4): 466-471. DOI: 10.11665/j.issn.1000-5048.20200412 |
[1] |
Long J, Etxeberria AE, Nand AV, et al. A 3D printed chitosan-pectin hydrogel wound dressing for lidocaine hydrochloride delivery[J]. Mater Sci Eng C Mater Biol Appl,2019,104:109873. doi: 10.1016/j.msec.2019. 109873.
|
[2] |
Chen YQ, Hong BH, Yi RZ. HPLC determination of contents and related substances in the tetrodotoxin lidocaine hydrochloride for injection[J]. Chin J Mar Drugs(中国海洋药物), 2016,35(3): 67-75.
|
[3] |
Wang X, Li X, Xiao Y. A novel dispersive liquid-liquid microextraction method with high performance liquid chromatography for detection of 2,6-dimethylaniline in lidocaine hydrochloride injection[J]. Se Pu,2018,36(3): 292-298.doi: 10.3724/SP.J.1123.2017.11049.
|
[4] |
Deng ZH, Li AH, Hu WJ. Improvement of quality control of lidocaine hydrochloride injection[J]. J Pharm Pract(药学实践杂志),2016(1):72-75.doi: 10.3969/j.issn.1006-0111.2016. 01. 019.
|
[5] |
Chinese Pharmacopoeia Commission.
|
[6] |
|
[7] |
The United States Pharmacopoeial Convention.
|
[8] |
Yang RY, Yin XL, Liang M, et al. Microscale experimental study on preparation of lidocaine[J]. Guangdong Chem Ind(广东化工),2010,37 (5):137, 149.doi: 10.3969/j.issn.1007-1865.2010.05.058.
|
[9] |
Zhejiang Huineng Biological Co., Ltd. Method for preparing lidocaine hydrochloride:
201510738390.7[P].2016-02-03. |
[10] |
Bengbu Fengyuan Pharmaceutical Technology Development Co., Ltd. Method for preparing lidocaine:
201010579590.X[P].2011-05-25. |
[11] |
Li M. Organic Chemistry of Drug Degradation[M]. United Kingdom: CPI Group (UK) Ltd, Croydon, CR04YY, UK,2012.
|
[12] |
Li Q, Magers T, King B, et al. Measurement of lidocaine and 2,6-dimethylaniline in minipig plasma, skin, and dermal tapes using UHPLC with electrospray MS/MS[J]. J Chromatogr B Analyt Technol Biomed Life Sci,2018,1087-1088:158-172. doi: 10.1016/j.jchromb.2018.04.030.
|
[13] |
Kobets T, Duan JD, Brunnemann KD, et al. DNA-damaging activities of twenty-four structurally diverse unsubstituted and substituted cyclic compounds in embryo-fetal chicken livers[J]. Mutat Res, 2019,844:10-24.doi: 10.1016/j.mrgentox.2019.06.004.
|
[14] |
Koujitani T., Yasuhara K., Kobayashi H., et al. Tumor‐promoting activity of 2,6‐dimethylaniline in a two‐stage nasal carcinogenesis model in N‐bis(2‐hydroxypropyl) nitrosamine‐treated rats[J]. Cancer Lett, 1999,142(2):161-171.
|
[15] |
The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.
|
[16] |
Heewon L. Pharmaceutical industry practices on genotoxic impurities[M]. US: CRC, 2015:87-88.
|
[17] |
Andrew T.Genotoxic impurities strategies for identification and control[M]. Canada: John Wiley & Sons, Inc., Hoboken, New Jersey, 2011: 44-46.
|
[18] |
Benigni R, Bossa C. Structure alerts for carcinogenicity, and the Salmonella assay system: a novel insight through the chemical relational databases technology[J]. Mutat Res,2008,659(3):248-261. doi: 10.1016/j.mrrev.2008.05.003.
|
[19] |
Xia YL, Zhang AJ, Liu JP. Optimization of tiopronin formulation[J]. Centr South Pharm(中南药学), 2015,13(7):739-740,779.
|
[20] |
Lei XX, Wang Y, Zhang JL, et al. Analysis of the addition and measurement of bacteriostatics and antioxidants in injection and eye drops[J]. Mod Chem Res(当代化工研究),2017 (4):143-144.
|
[1] | YE Zhenning, WU Zhenghong, ZHANG Huaqing. Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system[J]. Journal of China Pharmaceutical University, 2024, 55(5): 590-602. DOI: 10.11665/j.issn.1000-5048.2024052202 |
[2] | LUO Xuelian, WU Chengsheng, ZHA Cheng, LIU Sheng. Research progress and prospects of implantable drug delivery systems for postoperative tumor therapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 538-547. DOI: 10.11665/j.issn.1000-5048.2024040901 |
[3] | WANG Shihao, LIU Lifeng, DING Yang, LI Suxin. Research progress of pH-responsive drug delivery systems in cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 522-529. DOI: 10.11665/j.issn.1000-5048.2024011902 |
[4] | YU Jiayu, LIN Zezhi, CAO Wei, ZHANG Jianjun, WEI Yuanfeng, GAO Yuan, QIAN Shuai. Research progress of bio-metal organic frameworks in drug delivery system[J]. Journal of China Pharmaceutical University, 2023, 54(1): 23-33. DOI: 10.11665/j.issn.1000-5048.20221111003 |
[5] | ZHOU Yeshu, WANG Yanmei, ZHANG Beiyuan, WU Shuaicong, YANG Lei, YIN Lifang. Research progress of inorganic nanomaterials in drug delivery system[J]. Journal of China Pharmaceutical University, 2020, 51(4): 394-405. DOI: 10.11665/j.issn.1000-5048.20200403 |
[6] | LI Haoxian, LIN Huaqing, CHEN Jingwen, WANG Liyuan. Research progress of carbon nanomaterials in cancer drug delivery[J]. Journal of China Pharmaceutical University, 2019, 50(1): 100-106. DOI: 10.11665/j.issn.1000-5048.20190114 |
[7] | FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302 |
[8] | CHEN Xing, KANG Yang, WU Jun. Advances in biodegradable functional polymers based protein drug delivery system[J]. Journal of China Pharmaceutical University, 2017, 48(2): 142-149. DOI: 10.11665/j.issn.1000-5048.20170203 |
[9] | WANG Yazhe, ZHOU Jianping, DING Yang, WANG Wei. Advances in research of biomimetic drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(3): 267-273. DOI: 10.11665/j.issn.1000-5048.20140303 |
[10] | TANG Yue, KE Xue. Advances of mesoporous silica nanoparticles as drug delivery system[J]. Journal of China Pharmaceutical University, 2012, 43(6): 567-572. |